Targeted Alpha Therapies for Cancer Treatment: Global Market

PUBLISHED: September 11, 2025

PAGES: 81 Pages

DELIVERY TIME: 1-2 business days

SELECT AN OPTION

This report provides an overview of the global market for targeted alpha therapies for cancer and analyzes market trends. It includes global revenue ($ millions) for the base year data 2024 and estimated data for 2025, forecasted CAGRs through 2030.

Report Scope

The report provides an overview of the global market for targeted alpha therapies (TAT) for cancer and analyzes market trends. It includes global revenue ($ million) for the base year data 2024 and estimated data for the forecast period 2025 through 2030. The market is segmented based on cancer type.

The report focuses on trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report includes an analysis of the competitive landscape and pipeline analysis. A section dedicated to company profiles addresses key financials, product portfolios and recent developments involving industry leaders.

Report Includes

Overview and an analysis of the global market for targeted alpha therapies (TAT) for cancer treatment
Analyses of the global market trends, with historical market revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
Estimates of the current market size and revenue prospects of the global market, accompanied by a market share analysis by cancer type and region
Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
Insights derived from Porter's Five Forces model, and information on emerging trends and technologies, latest developments, and product pipeline analysis
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
A relevant patent analysis, featuring key granted and published patents
Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
Profiles of the leading companies

Product Code: PHM287A

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Emerging Technologies
Conclusion

Chapter 2 Market Overview

Overview
Macroeconomic Factors Analysis
Demographic Factors
Geopolitical Factors
Impact of the U.S. Tariff Laws
Porter's Five Forces Analysis
Potential of New Entrants: Moderate to Low
Bargaining Power of Suppliers: High
Bargaining Power of Buyers: Moderate
Threat of Substitute Products or Services: Moderate
Industry Competition: Low
Value Chain Analysis

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Increased Prevalence of Cancer
Demand for Precision Medicine
Unmet Treatment Need in Oncology
Increased Strategic Initiatives
Market Restraints
Supply Chain and Manufacturing Issues
Regulatory Hurdles
Market Challenges
Dosimetry Calculations
Recoil Effect
Market Opportunities
New Targets
Combination Therapies

Chapter 4 Regulatory Landscape

Regulatory Scenario
The U.S.
European Union
Japan

Chapter 5 Emerging Technologiesand Developments

Emerging Technologies
Advances in Drug Delivery Strategies
Theranostics
Pipeline Analysis
Key Takeaways

Chapter 6 Market Segmentation Analysis

Overview
Segmentation Breakdown
Market Analysis by Cancer Type
Key Takeaways
Prostate Cancer
Neuroendocrine Tumors
Other Cancers
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Key Takeaways
Market Analysis
Strategic Initiatives
Agreements, Collaborations and Partnerships
Acquisitions
Other Strategies

Chapter 8 Sustainability in Targeted Alpha Therapies for Cancer Treatment Market: An ESG Perspective

Introduction to ESG
Sustainability in the Targeted Alpha Therapies Industry
ESG Performance Analysis
Environmental Initiatives
Social Initiatives
Governance Initiatives
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Research Methodology
Sources
Abbreviations
Company Profiles
ACTINIUM PHARMACEUTICALS INC.
ADVANCELL PTY LTD.
BAYER AG
CONVERGENT THERAPEUTICS INC.
FUSION PHARM
NOVARTIS AG
ORANO MED
PERSPECTIVE THERAPEUTICS
RADIOMEDIX INC.
RAYZEBIO INC.
Emerging Startups in the Market

Product Code: PHM287A

List of Tables

Summary Table : Global Market for Targeted Alpha Therapies for Cancer Treatment, by Cancer Type, Through 2030
Table 1 : Common Characteristics, Production Methods, Delivery Strategies and Clinical Applications of Alpha-Emitters
Table 2 : Global Cancer Incidence and Mortality Rates, by the WHO Region, 2022
Table 3 : Strategic Initiatives in Targeted Alpha Therapy Market, 2023-2025
Table 4 : List of Selected Targeted Alpha Therapies, July 2025
Table 5 : Global Market for Targeted Alpha Therapies for Cancer Treatment, by Cancer Type, Through 2030
Table 6 : Agreements, Collaborations and Partnerships in the Targeted Alpha Therapies for Cancer Treatment Market, 2021-2025
Table 7 : Acquisitions in the Targeted Alpha Therapies for Cancer Treatment Market, 2021-2024
Table 8 : Other Strategic Initiatives in the Targeted Alpha Therapies for Cancer Treatment Market, 2022-2025
Table 9 : ESG Risk Rankings for Targeted Alpha Therapies Companies, 2025*
Table 10 : Information Sources in this Report
Table 11 : Abbreviations
Table 12 : Actinium Pharmaceuticals Inc.: Company Snapshot
Table 13 : Actinium Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 14 : Actinium Pharmaceuticals Inc.: Product Pipeline
Table 15 : Actinium Pharmaceuticals Inc.: News/Key Developments, 2023-2025
Table 16 : AdvanCell Pty Ltd.: Company Snapshot
Table 17 : AdvanCell Pty Ltd.: Product Pipeline
Table 18 : AdvanCell Pty Ltd.: News/Key Developments, 2023-2025
Table 19 : Bayer AG: Company Snapshot
Table 20 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 21 : Bayer AG: Product Portfolio
Table 22 : Bayer AG: News/Key Developments, 2021-2025
Table 23 : Convergent Therapeutics Inc.: Company Snapshot
Table 24 : Convergent Therapeutics Inc.: Product Pipeline
Table 25 : Convergent Therapeutics Inc.: News/Key Developments, 2021-2024
Table 26 : Fusion Pharma: Company Snapshot
Table 27 : Fusion Pharma: Product Pipeline
Table 28 : Fusion Pharma: News/Key Developments, 2024
Table 29 : Novartis AG: Company Snapshot
Table 30 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 31 : Novartis AG: Product Pipeline
Table 32 : Novartis AG: News/Key Developments, 2024
Table 33 : Orano Med: Company Snapshot
Table 34 : Orano Med: Product Pipeline
Table 35 : Orano Med: News/Key Developments, 2023-2025
Table 36 : Perspective Therapeutics: Company Snapshot
Table 37 : Perspective Therapeutics: Financial Performance, FY 2023 and 2024
Table 38 : Perspective Therapeutics: Product Pipeline
Table 39 : Perspective Therapeutics: News/Key Developments, 2024
Table 40 : RadioMedix Inc.: Company Snapshot
Table 41 : RadioMedix Inc.: Product Pipeline
Table 42 : RadioMedix Inc.: News/Key Developments, 2022-2025
Table 43 : RayzeBio Inc.: Company Snapshot
Table 44 : RayzeBio Inc.: Product Pipeline
Table 45 : RayzeBio Inc: News/Key Developments, 2024
Table 46 : Other Emerging Startups in the Targeted Alpha Therapies for Oncology Market

List of Figures

Summary Figure : Global Market Shares of Targeted Alpha Therapies for Cancer Treatment, by Cancer Type, 2030
Figure 1 : Porter's Five Forces Analysis of the Targeted Alpha Therapies for Cancer Treatment Market
Figure 2 : Targeted Alpha Therapies for Cancer: Value Chain Analysis
Figure 3 : Market Dynamics of Targeted Alpha Therapies for Cancer Treatment
Figure 4 : Cancer Incidence in the U.S., 2010-2022
Figure 5 : Clinical Trials Shares on Targeted Alpha Therapies, by Phase, as of July 2025
Figure 6 : Clinical Trials Shares on Targeted Alpha Therapies, by Study Type, July 2025
Figure 7 : Clinical Trials Shares on Targeted Alpha Therapies, by Study Status, as of July 2025
Figure 8 : Clinical Trials Shares on Targeted Alpha Therapies, by Radioisotope, as of July 2025
Figure 9 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
Figure 10 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
Figure 11 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 12 : Novartis AG: Revenue Shares, by Country/Region, FY 2024